title: MicroRNAs as therapeutic targets in cardiomyopathies: myth or reality?
abstract: The identification of biomarkers for cardiomyopathy presents a distinct challenge as the etiologies are widely varied. The discovery of small non-coding miRNAs with gene regulatory function has opened new avenues of investigation in basic and clinical sciences. The search for regulatory nucleotide sequences that have specific gene targets have put miRNAs at the forefront of development of therapeutics, and may serve as valuable diagnostic and/or therapeutic targets. MiRNAs appear to influence both positive and negative remodeling. As cardiac remodeling is a complex process, global molecular networks and miRNA profiles may be required to fulfill the roles of macroregulators. The type of cardiomyopathy leading to heart failure in the long run appears to have a distinct molecular pattern underlying the pathophysiology. This review discusses in brief the existing literature on the molecular signatures in dilated, ischemic, hypertrophic, stress, and peripartum cardiomyopathies that may be used to target therapies for specific etiologies once diagnosed, therefore exploring the utility of specific miRNAs in tailoring therapy for heart failure based on etiology.
authors.forename: Nandini
authors.initials: N
authors.lastname: Nair
authors.forename: Enrique
authors.initials: E
authors.lastname: Gongora
mesh_terms: D000818:Animals; D009202:Cardiomyopathies / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*; D006801:Humans; D035683:MicroRNAs / Q000378:metabolism*; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use
chemical_list: D035683:MicroRNAs; D016376:Oligonucleotides, Antisense